Emily Henkle1,2, Shannon A Novosad1, Sean Shafer2, Katrina Hedberg2, Sarah A R Siegel1, Jennifer Ku1, Cara Varley1, D Rebecca Prevots3, Theodore K Marras4, Kevin L Winthrop1. 1. 1 OHSU-PSU School of Public Health, Oregon Health & Science University, Portland, Oregon. 2. 2 Public Health Division, Oregon Health Authority, Portland, Oregon. 3. 3 Epidemiology Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; and. 4. 4 Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Abstract
RATIONALE: The natural history of nontuberculous mycobacteria (NTM) respiratory infection in the general population is poorly understood. OBJECTIVES: To describe the long-term clinical, microbiologic, and radiographic outcomes of patients with respiratory NTM isolates. METHODS: We previously identified a population-based cohort of patients with respiratory NTM isolation during 2005-2006 and categorized patients as cases or noncases using the American Thoracic Society/Infectious Diseases Society of America pulmonary NTM disease criteria at that time. During 2014-2015, we reviewed medical charts of patients alive on January 1, 2007. Outcomes of interest were the proportion of baseline noncases who later met case criteria and the proportions of patients with culture conversion or findings consistent with persistent disease at least 2-5 years and at least 5 years after first isolation. We defined disease persistence radiographically as infiltrate, nodules, or cavities and microbiologically as a positive respiratory mycobacterial culture. We used logistic regression to evaluate factors associated with evidence of persistence. RESULTS: The study included 172 patients (62% of 278 eligible); those not included either refused consent (n = 47) or were not located (n = 56). One hundred two (59%) included patients met case criteria at baseline. Mycobacterium avium complex was commonly isolated among baseline cases (n = 91 [89%]) and noncases (n = 52 [74%]). Overall, 57 (55%) baseline cases had died, as compared with 43 (61%) noncases (P = 0.47). Among baseline noncases, only four (5.7%) later met case criteria. Overall, 55 (54%) baseline cases and 6 (9%) noncases initiated NTM treatment. Among cases, cultures were converted in 25 (64.1%) treated versus 4 (40%) untreated patients (P = 0.04). Of 89 cases alive 2 years after isolation, 61 (69%) had additional radiography, and 35 (39%) had respiratory cultures. Of these individuals, 54 (89%) had radiographic evidence and 17 (49%) had microbiologic evidence of disease persistence. At 5 years after first isolation these figures were 36 (82%) and 13 (54%), respectively. Women were more likely to have persistent radiographic findings and microbiologic persistence, and patients with chronic obstructive pulmonary disease were less likely to have microbiologic persistence. CONCLUSIONS: In the general population, follow-up beyond 2 years of patients with respiratory NTM isolation is limited. Among those with additional evaluations, at least half of individuals have persistent positive cultures or radiographic findings consistent with NTM at least 2 years after isolation.
RATIONALE: The natural history of nontuberculous mycobacteria (NTM) respiratory infection in the general population is poorly understood. OBJECTIVES: To describe the long-term clinical, microbiologic, and radiographic outcomes of patients with respiratory NTM isolates. METHODS: We previously identified a population-based cohort of patients with respiratory NTM isolation during 2005-2006 and categorized patients as cases or noncases using the American Thoracic Society/Infectious Diseases Society of America pulmonary NTM disease criteria at that time. During 2014-2015, we reviewed medical charts of patients alive on January 1, 2007. Outcomes of interest were the proportion of baseline noncases who later met case criteria and the proportions of patients with culture conversion or findings consistent with persistent disease at least 2-5 years and at least 5 years after first isolation. We defined disease persistence radiographically as infiltrate, nodules, or cavities and microbiologically as a positive respiratory mycobacterial culture. We used logistic regression to evaluate factors associated with evidence of persistence. RESULTS: The study included 172 patients (62% of 278 eligible); those not included either refused consent (n = 47) or were not located (n = 56). One hundred two (59%) included patients met case criteria at baseline. Mycobacterium avium complex was commonly isolated among baseline cases (n = 91 [89%]) and noncases (n = 52 [74%]). Overall, 57 (55%) baseline cases had died, as compared with 43 (61%) noncases (P = 0.47). Among baseline noncases, only four (5.7%) later met case criteria. Overall, 55 (54%) baseline cases and 6 (9%) noncases initiated NTM treatment. Among cases, cultures were converted in 25 (64.1%) treated versus 4 (40%) untreated patients (P = 0.04). Of 89 cases alive 2 years after isolation, 61 (69%) had additional radiography, and 35 (39%) had respiratory cultures. Of these individuals, 54 (89%) had radiographic evidence and 17 (49%) had microbiologic evidence of disease persistence. At 5 years after first isolation these figures were 36 (82%) and 13 (54%), respectively. Women were more likely to have persistent radiographic findings and microbiologic persistence, and patients with chronic obstructive pulmonary disease were less likely to have microbiologic persistence. CONCLUSIONS: In the general population, follow-up beyond 2 years of patients with respiratory NTM isolation is limited. Among those with additional evaluations, at least half of individuals have persistent positive cultures or radiographic findings consistent with NTM at least 2 years after isolation.
Authors: D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier Journal: Am J Respir Crit Care Med Date: 2010-06-10 Impact factor: 21.405
Authors: David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop Journal: Am J Respir Crit Care Med Date: 2007-02-15 Impact factor: 21.405
Authors: Richard J Wallace; Barbara A Brown-Elliott; Steven McNulty; Julie V Philley; Jessica Killingley; Rebecca W Wilson; Deanna S York; Sara Shepherd; David E Griffith Journal: Chest Date: 2014-08 Impact factor: 9.410
Authors: Shannon A Novosad; Emily Henkle; Sean Schafer; Katrina Hedberg; Jennifer Ku; Sarah A R Siegel; Dongseok Choi; Christopher G Slatore; Kevin L Winthrop Journal: Ann Am Thorac Soc Date: 2017-07
Authors: Alexandra L Quittner; Anne E O'Donnell; Matthias A Salathe; Sandra A Lewis; Xiaoming Li; A Bruce Montgomery; Thomas G O'Riordan; Alan F Barker Journal: Thorax Date: 2014-10-16 Impact factor: 9.139
Authors: Theodore K Marras; David Mendelson; Alex Marchand-Austin; Kevin May; Frances B Jamieson Journal: Emerg Infect Dis Date: 2013-11 Impact factor: 6.883
Authors: Shannon A Novosad; Emily Henkle; Sean Schafer; Katrina Hedberg; Jennifer Ku; Sarah A R Siegel; Dongseok Choi; Christopher G Slatore; Kevin L Winthrop Journal: Ann Am Thorac Soc Date: 2017-07
Authors: Sarah K Brode; Hannah Chung; Michael A Campitelli; Jeffrey C Kwong; Alex Marchand-Austin; Kevin L Winthrop; Frances B Jamieson; Theodore K Marras Journal: Emerg Infect Dis Date: 2019-07 Impact factor: 6.883
Authors: Mary A De Groote; Thale C Jarvis; Christina Wong; James Graham; Teresa Hoang; Casey L Young; Wendy Ribble; Joshua Day; Wei Li; Mary Jackson; Mercedes Gonzalez-Juarrero; Xicheng Sun; Urs A Ochsner Journal: Front Microbiol Date: 2018-09-20 Impact factor: 5.640
Authors: Christina M Mingora; Bryan A Garcia; Kevin C Mange; Dayton W Yuen; Monika Ciesielska; Jakko van Ingen; Patrick A Flume; Susan E Dorman Journal: BMC Infect Dis Date: 2022-03-12 Impact factor: 3.090